New drug SB 44

[Bob0620]

By Spring bank pharma.

Any info on this ?

Link : http://www.niaid.nih.gov/about/organization/dmid/success/Pages/SB44.aspx

http://www.springbankpharm.com/hepatitis.html

Summary :

SB 9200 is a potential breakthrough drug for HBV and HCV. It has both direct antiviral and immune stimulating activities. Its works by activating RIG-I, a human protein involved in the detection of viral RNA in cells, so it is unlikely to elicit resistance. It shows synergy in combination with other antiviral drugs and has activity against drug-resistant viral strains. SB 9200 is orally available and was well tolerated in IND enabling toxicology studies. With this profile, it could potentially replace ribavirin and/or interferon in combination therapy.

[Royal36]

Phase II clinical trials for SB 9200 in HBV-infected patients are expected to begin in late 2015.

[sorte]

yep. study finishes in April https://clinicaltrials.gov/ct2/show/NCT02065336

[Royal36]

: $ARWR according to the Barclay's presentation, ARC520 data to be reported 'end of Q2',hope some good news.

[seza1981]

you are welcome

[sorte]

thanks :) good to know that somethings going on

[seza1981]

they have a presentation at March 20-21, 2015

http://www.760kfmb.com/story/28405619/spring-bank-pharmaceuticals-to-present-novel-approach-to-hepatitis-b-treatment-at-the-2015-aasld-and-industry-colloquium

[sorte]

I can not find anywhere results of Phase I :/

[sorte]

update

http://springbankpharm.com/spring-bank-pharmaceuticals-completes-22-million-financing-proceeds-support-phase-ii-clinical-development-sb-9200-hepatitis-b/

[veteranB]

That is good news but at the rate they move to approve these things it takes  10 or more years. There just has to be a better way to all this.

[Bob0620]

Just found out about this new drug. Will try to get more info.

[4est]

http://www.springbankpharm.com/hepatitis.html

[4est]

"After successful preclinical studies, this new oral drug, now called SB 44, may soon be moving into clinical trials to test its effectiveness in humans for the treatment of chronic HBV infections."  - do you know were this preclinical test were done ?

[StephenCastlecrag]

Thanks. It looks interesting, but very few details:
SB 9200 Activates RIG-I, Stimulating Interferon Production and Also Interferes Directly with Viral Replication

     • Activates RIG-I and triggers the signaling cascade for antiviral action  
     • Interferes with viral proteins by preventing them from binding, blocking their
        progression or displacing them from viral RNA thereby inhibiting viral replication.